Fyn Knock-Down Prevents Levodopa-Induced Dyskinesia in a Mouse Model of Parkinson's Disease | eNeuro
Brain Sciences | Free Full-Text | Transcriptome Sequencing Reveal That Rno-Rsf1_0012 Participates in Levodopa-Induced Dyskinesia in Parkinson’s Disease Rats via Binding to Rno-mir-298-5p | HTML
Profile of levodopa/carbidopa intestinal gel and its potential in the | JPRLS
The human experience with intravenous levodopa
Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia— Literature Review
Frontiers | A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease
PDF) Levodopa-induced dyskinesias in Parkinson's disease: Emerging treatments
PDF) Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients
PDF) Continuous levodopa for advanced Parkinson's disease
Time course for AIM scores following levodopa. Rats were treated daily... | Download Scientific Diagram
Levodopa-Induced Dyskinesia in Parkinson Disease: Current and Evolvin…
Frontiers | The Human Experience with Intravenous Levodopa
Levodopa-Induced Dyskinesia in Parkinson's Disease
![PDF] Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease](https://i1.rgstatic.net/publication/320469061_LevodopaBenserazide_Loaded_Microspheres_Alleviate_L-dopa_Induced_Dyskinesia_through_Preventing_the_Over-Expression_of_D1RShp-2ERK12_Signaling_Pathway_in_a_Rat_Model_of_Parkinson's_Disease/links/59e752f24585152d5f04deb6/largepreview.png "PDF] Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease")
PDF] Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease
PDF) Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease
Striatal Glutamate Release in l-DOPA-Induced Dyskinetic Animals | PLOS ONE
The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study - ScienceDirect
PDF) Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation
PDF) Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
Frontiers | Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson's Disease: A Perspective Through Preclinical and Clinical Evidence
PDF) Levodopa-induced plasticity: A double-edged sword in Parkinson's disease
Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone
PDF) Levodopa-induced dyskinesia in Parkinson disease: Current and Evolving Concepts: Dyskinesia in Parkinson disease
Biomolecules | Free Full-Text | Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease | HTML
Melanomas y carcinomas basocelulares en un paciente con enfermedad de Parkinson
Frontiers | The Human Experience with Intravenous Levodopa
